Research programme: HIV vaccines - GenVec

Drug Profile

Research programme: HIV vaccines - GenVec

Alternative Names: HIV adenovector serotype Ad41 vaccine - GenVec/NIAID; Second-generation HIV vaccines - GenVec/SAIC-Frederick

Latest Information Update: 09 Jul 2014

Price : $50

At a glance

  • Originator GenVec
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 28 Mar 2014 Discontinued - Preclinical for HIV-1 infections in USA (Parenteral)
  • 04 Sep 2013 Research programme: HIV vaccines - GenVec is available for licensing as of 04 Sep 2013. http://www.genvec.com/
  • 06 Oct 2010 GenVec receives second-year funding for development of HIV vaccines under 4-year contract with SAIC-Frederick
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top